Considering the diverse treatment strategies, such as chemotherapy, employed for distinct CRC subtypes, the characterization of miR-4442 and RBMS1 in relation to these subtype differences is of considerable interest. This evidence concerns the gene RBMS1 and colorectal carcinoma.